Source: GPLP Rhino Finance (ID: gplpcn)

On June 18, the official website of the Shenzhen Stock Exchange showed that the IPO review status of Shenzhen Han’s CNC Technology Co., Ltd. (hereinafter referred to as “Han’s CNC”) was changed to “Inquired”.

It is reported that Han’s CNC intends to issue no more than 42 million shares this time, and raise funds of approximately 1.707 billion yuan, which will be used for equipment production transformation and expansion and equipment technology research and development center construction projects.

Han’s Laser Splits the Pledge of Han’s CNC Listed Shares

The prospectus shows that Han’s CNC was established in 2002. Its main business is the research and development, production and sales of PCB special equipment. The registered capital is 378 million yuan. The controlling shareholder is Han’s Laser (002008.SZ). Han’s Laser directly holds 94.15% of the company’s shares.

In addition, the actual controller of Han’s CNC is Gao Yunfeng, who directly holds 9.03% of Han’s Laser, and indirectly controls 15.17% of Han’s Laser through Han’s Holdings, and controls a total of 24.20% of Han’s Laser.

The Han’s Laser’s split and listing of Han’s CNC also caused investors to worry.

On May 27, an investor asked Han’s Laser that there are a large number of related transactions and related guarantees between the parent company and listed subsidiaries. How does the company deal with such problems? It is true that the splitting of subsidiaries can better obtain financing to facilitate the further development of the subsidiaries, but it is an act at the expense of all investors. Does Han’s Laser consider the position of investors?

Han’s Laser stated that after this spin-off, Han’s Laser and Han’s CNC have no related party transactions that affect independence or are obviously unfair, which meets the requirements of the China Securities Regulatory Commission and the Shenzhen Stock Exchange on related party transactions.

However, GPLP Rhino Finance noticed that Han’s Holdings and Gao Yunfeng’s holding of Han’s Laser pledged shares have certain risks, which may indirectly affect the stability of Han’s CNC decision-making and management and the company’s production and operation.

As of April 30, 2021, the cumulative number of pledged shares of Han’s Laser held by Han’s Holdings was 5.36 million shares, accounting for 36.68% of its holdings and 5.56% of Han’s Laser’s total share capital.

The accumulated pledged shares of Han’s Laser held by Gao Yunfeng are 89.140 million shares, accounting for 92.55% of the shares held by him and 8.35% of the total share capital of Han’s Laser. The total number of pledged shares of Han’s Laser held by Han’s Holdings and Mr. Gao Yunfeng totaled 149 million shares, accounting for 57.52% of the shares held by the two and 13.92% of the total share capital of Han’s Laser.

GPLP Rhino Finance noted that the sponsor of Han’s CNC this time is CITIC Securities Co., Ltd. (hereinafter referred to as “CITIC Securities”). As of December 31, 2020, CITIC Securities held approximately 1.0635 million shares of Han’s Laser, accounting for approximately 0.10% of Han’s Laser’s total equity. Han’s CNC stated that if Han’s Holdings and Gao Yunfeng cannot repay the loan on or before the due date of the guaranteed loan, the pledged Han’s Laser shares may be subject to the risk of forced disposal, which may lead to changes in the equity structure of Han’s Laser, which may be indirect Affect the stability of Han’s CNC decision-making and management and the company’s production and operation. There are still connected transactions with Han’s Laser, and the high cash flow of accounts receivable is under pressure However, Han’s CNC still has connected transactions with Han’s Laser. From 2018 to 2020, the related sales amount of Han’s CNC is 17.2676 million yuan, 48.292 million yuan and 22.107 million yuan respectively. The sales between Han’s CNC and related parties are mainly the sale of laser forming machines and mechanical drilling machines to the controlling shareholder Han’s Laser, and the testing and sales of mechanical forming machines and mechanical drilling machines to the associated company Mingxin. The related-party purchase transactions of Han’s CNC were 127 million yuan, 60 million yuan and 118 million yuan respectively. The purchases between the company and related parties are mainly purchases of chillers, linear motors, lasers, etc. from the controlling shareholder and its controlled companies Han’s Motor and Han’s Tiancheng. Can the performance of Han’s Laser be able to maintain steady growth without Han’s Laser’s Han’s CNC? The prospectus shows that Han’s CNC has seen a sharp decline in its performance in 2019, and will only pick up in 2020. From 2018 to 2020, Han’s CNC’s operating income was 1.723 billion yuan, 1.323 billion yuan, and 2.21 billion yuan, and net profits were 374 million yuan, 227 million yuan, and 304 million yuan. The revenue growth rates in 2019 and 2020 are -23.24% and 67.10% respectively; the net profit growth rates are -39.25% and 33.86% respectively. Despite the support of Han’s Laser, the gross profit margin of Han’s CNC is far lower than the industry average. From 2018 to 2020, Han’s CNC’s gross profit margins were 34.03%, 35.90%, and 34.92%, while the industry averages over the same period were 49.94%, 46.52%, and 44.01%, respectively. (Source: Han’s CNC Prospectus) In addition, the inventory of Han’s CNC has increased year by year and accounted for a relatively high proportion. From the end of 2018 to the end of 2020, the company’s inventory book value was 246 million yuan, 261 million yuan, and 799 million yuan, accounting for 14.32%, 15.19%, and 28.69% of current assets, respectively. From the end of 2018 to the end of 2020, the total book value of Han’s CNC’s notes and accounts receivable was 1.124 billion yuan, 972 million yuan, and 1.269 billion yuan, accounting for 65.51%, 56.66%, and 45.56% of current assets, respectively. In this regard, Han’s CNC stated that in 2020, due to the increase in orders for PCB special equipment, the company increased its inventory, resulting in a relatively high inventory balance. Han’s CNC stated that the high inventory balance will occupy a large amount of its working capital on the one hand, which puts the company under pressure on working capital; on the other hand, if there is an order cancellation or customer return due to changes in customer demand or major adverse changes in operating conditions Circumstances, may lead to the risk of stagnation and impairment of inventory, and the company’s operating results will be adversely affected. GPLP Rhinoceros Finance noted that in 2020, the substantial increase in operating receivables combined with the accumulation of inventory, Han’s CNC’s net operating cash flow turned from positive to negative. From 2018 to 2020, its net operating cash flow was 185 million yuan, 270 million yuan, and -509.714 million yuan. Han’s CNC stated that if the company cannot obtain financing in a timely manner, it may result in insufficient business operating funds, which will further negatively affect its financial status and production operations. (This article is for reference only, does not constitute investment advice, and operates at your own risk accordingly)

Image source: Shanghai Stock Exchange official website

The company develops, produces and sells molecular diagnostic reagents and equipment integrated products based on this, focusing on precise diagnosis, effective prevention and control, and personalized diagnosis and treatment of pathogens in the fields of reproduction, breathing, digestion, blood, food, environmental safety, etc. provide the solution.

Picture source: company prospectus

Financial data shows that the company’s revenue in 2018, 2019, and 2020 were 69,343,400 yuan, 99,168,100 yuan, and 250 million yuan, respectively; during the same period, the corresponding revenues were -32,0512 million, 3,379,200 yuan, and 61,376,500 yuan respectively. After the non-deduction, both 2018 and 2019 lost money.

In 2020, the issuer will realize RMB 249,903,400, net profit of RMB 61,376,500, net profit after deduction of RMB 53,281,600. Based on the company’s latest external situation and the valuation of comparable companies in domestic and overseas markets, the issuer expects the valuation to be no less than RMB 1 billion.

The issuer’s selection criteria for listing is Article (1) stipulated in Chapter 2.1.2 of the “Shanghai Science and Technology Innovation Board Stock Listing Rules”: the estimated market value is not less than RMB 1 billion, and the net profit in the most recent year is positive and operating The income is not less than RMB 100 million. This fundraising is planned to be used for industrialization R&D projects of precision diagnostic reagents and smart equipment, and marketing network construction projects. Picture source: company prospectus Rendu Biotech is backed by Suzhou Qiming, Yida Talent, Jinxin Venture Capital, etc. Rendu Biotech frankly stated that the company faces the following risks: (1) New product development risks The issuer’s in vitro diagnostic industry is a typical technology-driven industry. The research and development of new products has the characteristics of strong technical integration, large capital investment, and long cycle. Whether the company can continuously develop new products that meet market needs is whether the company can One of the key factors for maintaining a leading position in industry competition. Therefore, in the process of new product development, the issuer may face the risk of R&D failure due to deviations in the R&D direction, slow R&D process, and high R&D investment costs. (2) Risk of falling product prices According to the current relevant national regulations, the highest price standards for non-profit medical institutions that enter the “Clinical Testing Project Catalog” are set and adjusted by the local price authorities. With the deepening of the national medical reform and the further adjustment of relevant policies and regulations, the relevant competent authorities may lower the prices of some test items. With the further deepening of my country’s medical treatment, the company’s product sales prices may be affected by policy factors such as bidding policies and hospital procurement regulations. In addition, with the increase of market participants and the intensified competition, the price of corresponding diagnostic reagent products will also be lowered. If the company cannot continue to increase R&D investment and launch new products in the future, or is affected by factors such as government price adjustments, bidding policies, and market competition, the company will face risks related to product prices. (3) New technology market acceptance risk During the reporting period, the issuer focused on RNA molecular diagnostic technology and products, and its main business was R&D, production and sales of molecular diagnostic reagents and equipment integrated products based on the RNA real-time fluorescent constant temperature amplification technology (SAT) platform. Compared with the DNA molecular diagnostics that appeared in the 1980s and 1990s, RNA molecular diagnostics appeared later, and the current market awareness is low. The proportion of RNA in the field of infectious molecular diagnostics in China is only 6%, and the penetration rate is relatively low. 25% in developed markets in the United States is lower. At the same time, unlike the development path of DNA molecular diagnostics used by comparable listed companies in the same industry, the issuer focuses on RNA molecular diagnostics. If the company’s market development and academic promotion are insufficient in the future, the market structure and needs change, the company cannot successfully achieve market promotion, or the clinical market fails to be more familiar with and accept the company’s RNA molecular diagnostic products, this will result in the company’s market development, which may affect the company. The future and sales growth will have certain adverse effects. (4) The risk of performance fluctuations caused by the new coronavirus epidemic At the beginning of 2020, the new coronavirus epidemic broke out in my country. The issuer successfully developed a new coronavirus 2019-nCoV nucleic acid detection kit with high-throughput automatic detection equipment based on a systematic technology platform and an efficient R&D system. And through the emergency approval of the State Drug Administration, the registration certificate was obtained on March 26, 2020. Combined with the company’s fully automatic nucleic acid detection and analysis system, it can realize the automatic, integrated, and on-the-go detection of new coronavirus detection. It is an enterprise that realized the automatic detection of new coronavirus early in China, and it is rapidly mass-produced for the prevention and control of new coronary pneumonia. make a contribution. The company’s new crown detection kit revenue in 2020 will be 68,507,400 yuan, accounting for 27.41%. With the advent of the new crown vaccine and the effective control of the epidemic by government departments, the company’s new crown detection kit income is at risk of decreasing. Hospitals at all levels across the country actively responded to the call of the state in the early stage of epidemic prevention and control, and invested a large number of medical staff and health resources in the epidemic prevention and control battle, causing their normal diagnosis and treatment business to be suspended. Since the company’s reproductive tract and intestinal products are mainly used in hospital reproductive departments, pediatrics and other departments, during this epidemic, in order to concentrate efforts to fight the epidemic and reduce the risk of cross-infection in the hospital, the above departments were partially or completely closed, resulting in The sales of related products of the company will be affected to a certain extent in the short term. At present, the new coronavirus epidemic has been effectively controlled nationwide, but the impact of foreign epidemic outbreaks, imported cases and virus mutations may lead to greater uncertainty in the epidemic, which will cause fluctuations in the company’s business performance growth. (5) Risks of investment projects with raised funds The funds raised by the company this time are mainly used for industrialization R&D projects of precision diagnostic reagents and intelligent equipment and marketing network construction projects. The construction of the above-mentioned fund-raising investment projects will enhance the company’s in vitro diagnostic reagent product structure, and at the same time, through the update and upgrade of instruments, it will effectively enhance the market competitiveness of the company’s products, increase the company’s sales scale and thereby enhance the company. Although the company has conducted a prudent feasibility demonstration for the raised funds investment projects, due to the large amount of funds raised, if the raised funds are not in place as scheduled, the project implementation organization is poorly managed, or the downstream market demand changes adversely, the raised funds will be affected. The construction progress and investment benefits of capital investment projects have an adverse impact. In addition, the issuer’s raised funds investment project will significantly increase R&D investment and marketing team building expenses in the early stage of construction. There is a risk that the company’s profitability will decline due to increased expenses. At the same time, the company’s net assets will increase significantly. Since it takes a certain amount of time from the beginning of the implementation of the fund-raising investment project to produce the expected benefits, the company has the risk of a decline in the return on net assets

Illustration. (Photo: Vietnam+) With the goal of improving efficiency, bringing more conveniences and incentives to customers when using products and services, Joint Stock Commercial Bank for Industry and Trade of Vietnam (VietinBank) deploys free notification of transaction fluctuations translation for owner credit (international and domestic). Accordingly, from June 1, VietinBank will free and change the transaction notification channel from SMS to OTT message channel on VietinBank iPay Mobile application for all credit card and current customers. using VietinBank’s digital banking services. OTT messages on VietinBank iPay Mobile application help customers receive transaction notifications 24/24 even while working or traveling abroad, just need to have an Internet connection with the device that has installed the application. In addition, OTT news with no character limit with clear and complete message content will help customers manage their accounts in the best way. VietinBank hopes that the form of notification of transaction fluctuations via OTT messages directly on VietinBank iPay Mobile will help customers have a safe and secure experience for customers when using VietinBank’s products and services. For customers who have not installed VietinBank iPay Mobile application, VietinBank will continue to send SMS messages and provide free services to customers./.

Accordingly, from June 1, 2021, VietinBank will free and change the transaction notification channel from SMS to OTT message channel on VietinBank iPay Mobile application for all credit card customers. and are using VietinBank’s digital banking service. OTT messages on VietinBank iPay Mobile application help customers receive transaction notifications 24/24 even while working or traveling abroad, just need to have an Internet connection with the device that has installed the application. In addition, OTT news with no character limit with clear and complete message content will help customers manage their accounts in the best way. VietinBank hopes that the form of notification of transaction fluctuations via OTT messages directly on VietinBank iPay Mobile will help customers have a great experience and ensure safety and security for customers when using products. , services of VietinBank. For customers who have not installed VietinBank iPay Mobile application, VietinBank will continue to send SMS messages and provide free services to customers. For more information, please contact the nearest VietinBank branch/transaction office, Customer Support Center: 1900 558 868 or Email: contact@vietinbank.vn.